Article
Oncology
Yingying Chen, Huan Tao, Fujue Wang, Pengqiang Wu, Jie Gao, Xue Zhang, Zhengcang He, Zhencang Zhou, Yongqian Jia
Summary: The study aimed to investigate the synergistic effects of ART and SOR in lymphoma treatment, and the underlying mechanisms. The results demonstrated that ART and SOR synergistically inhibited cell proliferation, induced apoptosis and ferroptosis, and regulated the STAT3 pathway.
Review
Biochemistry & Molecular Biology
Anwar Zaiter, Zahraa F. Audi, Fatima Shawraba, Zahraa Saker, Hisham F. Bahmad, Rami H. Nabha, Hayat Harati, Sanaa M. Nabha
Summary: Medulloblastoma is the most common malignant brain tumor of childhood, with improved overall survival rate but still lacking efficient and reliable therapeutic approaches. Understanding the role of signal transducer and activator of transcription 3 in medulloblastoma tumorigenesis is crucial for the development of effective therapies.
MOLECULAR BIOLOGY REPORTS
(2022)
Article
Pharmacology & Pharmacy
Ge Jin, Lintao Wang, Jun Ma
Summary: Cardiac hypertrophy is a compensatory response to chronic pressure overload, and excessive angiotensin II plays a significant role in inducing cardiac hypertrophy. Previous studies have shown that STAT5, a member of the STATs family, is closely linked to non-tumor diseases, but its specific role in hypertrophy progression remains unclear. In this study, STAT5-IN-1, a STAT5 inhibitor, was administered to mice and H9c2s cells were used as cell models to investigate the effects of STAT5-IN-1 on cardiac hypertrophy induced by angiotensin II. The findings demonstrated that STAT5 inhibitor substantially decreased cardiac hypertrophy by reducing inflammation.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Review
Cell Biology
Jianbiao Zhou, Wee-Joo Chng
Summary: This article summarizes the role of STAT3 in multiple myeloma (MM), including its involvement in cell survival and proliferation, regulation of the tumor microenvironment, and induction of immunosuppression. The article also provides updates on different strategies for targeting STAT3 in MM, with a focus on JAK inhibitors currently undergoing clinical trials. Finally, the challenges and future directions of understanding STAT3 signaling and developing STAT3 inhibitors in MM are discussed.
Article
Biology
Zhifa Shen, Bowen Liu, Biting Wu, Hongyin Zhou, Xiangyun Wang, Jinling Cao, Min Jiang, Yingying Zhou, Feixia Guo, Chang Xue, Zai-Sheng Wu
Summary: The study proposes a mechanism for the metastasis of hepatocellular carcinoma (HCC) cells by regulating the localization and translation of the STAT3 oncogene through fragile X mental retardation protein (FMRP). Knockdown of FMRP suppresses HCC metastasis effectively.
COMMUNICATIONS BIOLOGY
(2021)
Article
Infectious Diseases
Zhao-Ming Chen, Xiao-Yun Yang, Zheng-Tu Li, Wei-Jie Guan, Ye Qiu, Shao-Qiang Li, Yang-Qing Zhan, Zi-Ying Lei, Jing Liu, Jian-Quan Zhang, Zhong-Fang Wang, Feng Ye
Summary: The presence of anti-IFN-gamma autoantibodies inhibits immune responses of CD4(+) Th1 and CD8(+) T cells, and increases the release of IL-10.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Medicine, Research & Experimental
Jiameng Lu, Xiaoqing Ji, Lixia Wang, Fei Sun, Chuanjun Huang, Haiying Peng, Yunxiu Jiang, Zihan Guo, Xinyi Liu, Yanbo Ji, Degan Lu
Summary: This study found that prophylactic administration of IL-27 can improve asthma by restoring the STAT1 and STAT3 pathways, alleviating the Th2 inflammatory environment in the lungs.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Haoran Li, Dingan Luo, Lakshmi Huttad, Mao Zhang, Youpeng Wang, Juan Feng, Yunfeng Ding, Bing Han
Summary: The study revealed the association between RIPK4 and the prognosis of HCC patients, showing that its overexpression inhibits invasion and metastasis in HCC through mechanisms involving the EMT and STAT3 pathways. Targeted inhibition of RIPK4 and the STAT3 pathway may offer potential therapeutic strategies to prevent postoperative recurrence and metastasis in HCC.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2021)
Article
Obstetrics & Gynecology
Sachiko Matsuzaki, Jean-Luc Pouly, Michel Canis
Summary: Persistent activation of signal transducer and activator of transcription 3 (STAT3) via interleukin-6 (IL-6) trans-signaling is involved in fibrosis of endometriosis.
HUMAN REPRODUCTION
(2022)
Article
Chemistry, Medicinal
Peng He, Ying Miao, Yue Sun, Aiwu Bian, Wangrui Jin, Jiangnan Ye, Huang Chen, Jia He, Yangrui Peng, Haijun Gu, Mingyao Liu, Zhengfang Yi, Yihua Chen
Summary: This study describes the design, synthesis, and structure-activity relationship studies of triaromatic heterocyclic derivatives as potent dual phosphorylation STAT3 inhibitors. The best compound 3h (HP590) was discovered with high inhibitory activity against p-Tyr(705) and p-Ser(727), resulting in the growth inhibition of gastric cancer both in vitro and in vivo.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Yuhan Su, Tianyu Tao, Xiuxing Liu, Wenru Su
Summary: This review summarizes the diverse roles of the JAK-STAT signaling pathway in ocular homeostasis and non-infectious uveitis (NIU) pathology, and discusses the safety and efficacy of JAK inhibitors for treating NIU and potential approaches for treatment optimization.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Oncology
Qi Huang, Jing Li, Mengqing Ma, Minling Lv, Rui Hu, Jialing Sun, Xin Zhong, Xinfeng Sun, Wenxing Feng, Wenfeng Ma, Wei Zhang, Bolin Zhan, Zhiyi Han, Xiaozhou Zhou
Summary: Polyphyllin VI, a natural herbal compound, was identified as a potential therapeutic drug for hepatocellular carcinoma (HCC). It inhibits the proliferation, invasion, and metastasis of HCC cells by inducing ferroptosis through the inhibition of the STAT3/GPX4 axis. These findings suggest that polyphyllin VI may have potential for the prevention and treatment of HCC.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Matteo Santoni, Francesca Miccini, Alessia Cimadamore, Francesco Piva, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Nicola Battelli
Summary: Researchers provided an overview of STAT3 inhibitors and examined the latest research results in cancer patients. They discussed recent publications since 2015 and ongoing clinical trials on anti-STAT3 agents in cancer patients. Future challenges include developing non-peptide small-molecule inhibitors of STAT3 and enhancing understanding of STAT3's role in modulating immune response.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Cell Biology
JaeSang Ko, Ji-Young Kim, Bo Ram Kim, Eun Jig Lee, Don O. Kikkawa, Jin Sook Yoon
Summary: In this study, higher expression of STAT3 mRNA was found in orbital tissues from Graves’ orbitopathy (GO) patients compared to non-GO tissues. STAT3 expression was induced by proinflammatory cytokines in GO orbital fibroblasts but not in non-GO cells, and STAT3 silencing inhibited inflammatory cytokine production and oxidative stress responses while decreasing adipocyte differentiation in GO orbital fibroblasts. These findings suggest that STAT3 plays a crucial role in inflammation, oxidative stress, and adipogenesis in GO, and modulating STAT3 expression may have therapeutic potential against GO.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Review
Oncology
Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, Weimin Yi, Chuang Peng, Sulai Liu
Summary: Intrahepatic cholangiocarcinoma (ICC) is a primary malignant liver tumor with a poor prognosis, characterized by neoplastic transformation of intrahepatic biliary epithelial cells. Signal transducer and activator of transcription 3 (STAT3) is an important oncogene that may serve as a target for ICC treatment. Further research is needed to improve understanding of STAT3 and its role in ICC development.
MOLECULAR MEDICINE REPORTS
(2022)
